Although major depressive disorder is primarily considered a mood disorder, depressed
patients commonly present with clinically significant cognitive dysfunction that may add to …

In the past, little or no attention was paid to cognitive disorders associated with depression
(a condition sometimes termed pseudodementia). However, recent years have seen a …

Objectives: Vortioxetine has already shown its efficacy in the acute and long-term treatment
of major depressive disorder (MDD) and its potential interest in the prevention of relapse …

Cognitive dysfunction is common in depression during both acute episodes and remission.
Vortioxetine is a novel multimodal antidepressant that has improved cognitive function …

Abstract Background Major Depressive Disorder (MDD) is a heterogeneous disease
characterized by emotional, physical and cognitive symptoms. This study explored the …

Abstract Vortioxetine (Brintellix®; Trintellix®), a generally efficacious and well tolerated
antidepressant agent, is approved in the EU and USA for the treatment of major depressive …

Major Depressive Disorder (MDD) is a prevalent, chronic, disabling, and multidimensional
mental disorder. Cognitive dysfunction represents a core diagnostic and symptomatic …

Background Cognitive dysfunction in major depressive disorder (MDD) encompasses
several domains, including but not limited to executive function, verbal memory, and …

Introduction: Vortioxetine is a pharmacodynamically novel antidepressant that exerts effects
on various neurotransmitters including serotonin, noradrenaline, dopamine, glutamate …

Background: Cognitive dysfunction is a core transdiagnostic domain of Major Depressive
Disorder (MDD) and is a principal determinant of functional recovery. However, it has been …